Imtesty,

I don't really have anything to add to your musing on the cognition/vascular cognitive dementia effects of apabetalone. Promising preliminary data; however, there were only 30 apabetalone treatment patients and 45 placebo patients in that baseline MoCA<22 subgroup that showed the benefit. The p-values were just under 0.05 for the data in slides 4 and 6 looking at change in total MoCA score in this subgroup. So while it is good that the comparison was p<0.05, this is not exactly outstanding statistical significance. Combined with the small number of patients, this does not bolster much confidence in reproducibility. Plus, after hearing that a certain leader of a certain country "aced" this MoCA test despite ongoing concerns of this leader's cognitive function, I am starting to really question the reliability and utility of the MoCA test.

BDAZ